Plettenberg A, Albrecht D, Lorenzen T, Paech V, Petersen H, Fenner T, Meyer T, Arndt R, Hertogs K, Pauwels R, Weitzel T, Stoehr A
General Hospital St Georg, Hamburg, Germany.
Sex Transm Infect. 2001 Dec;77(6):449-52. doi: 10.1136/sti.77.6.449.
To assess HIV-1 isolate based resistance profiles from extensively pretreated patients and effects of a resistance guided switch of antiretroviral therapy.
In a prospective study phenotypic and genotypic resistance analyses were performed on HIV infected individuals with failure of the current therapy and history of at least three antiretroviral regimens. Antiretroviral therapy was changed according to the results. Viral load and CD4 lymphocyte counts were measured at baseline, after 10 (SD 2), and 24 (2) weeks.
All patients (n=52) failed their actual regimen. Currently versus ever previously taking the specific drug, resistance associated mutations and phenotypic resistance to AZT and 3TC were found in over 80% of individuals; resistance to DDI and D4T was detected in less than 10% of cases. A resistance guided switch of therapy was followed by a median decrease of viral load of 0.5 log10 units after 24 weeks. Individuals resistant to two or more drugs compared with patients with resistance to less than two drugs of ongoing treatment, were switched to a regimen containing DDI, D4T, and a PI or NNRTI. After 10 (SD 2) weeks viral load decrease was pronounced in patients with resistance to at least two drugs in the previous regimen.
Among different RTI, the profile of clinically relevant resistance indicates pronounced differences when looking at separate drugs. Regarding virological response, in the context of available drugs, resistance tested with currently used methods is of limited value in extensively pretreated patients and seems to have its value primarily in first or second switch of therapy.
评估接受过大量治疗的患者中基于HIV-1分离株的耐药谱以及耐药性指导下的抗逆转录病毒疗法转换的效果。
在一项前瞻性研究中,对当前治疗失败且至少接受过三种抗逆转录病毒治疗方案的HIV感染者进行了表型和基因型耐药性分析。根据结果更改抗逆转录病毒疗法。在基线、10(标准差2)周和24(2)周后测量病毒载量和CD4淋巴细胞计数。
所有患者(n = 52)当前治疗方案均失败。与曾经服用过特定药物相比,超过80%的个体中发现了与AZT和3TC相关的耐药性突变和表型耐药性;不到10%的病例检测到对DDI和D4T的耐药性。在耐药性指导下进行治疗转换后,24周后病毒载量中位数下降了0.5 log10单位。与正在接受治疗且耐药性少于两种药物的患者相比,对两种或更多种药物耐药的个体被转换为包含DDI、D4T以及一种蛋白酶抑制剂(PI)或非核苷类逆转录酶抑制剂(NNRTI)的治疗方案。在10(标准差2)周后,对前一种治疗方案中至少两种药物耐药的患者病毒载量明显下降。
在不同的核苷类逆转录酶抑制剂(RTI)中,当单独观察每种药物时,临床相关耐药谱显示出明显差异。关于病毒学反应,在现有药物的背景下,用当前使用的方法检测的耐药性在接受过大量治疗的患者中价值有限,其价值似乎主要体现在首次或第二次治疗转换中。